NCT07782827Phase 3Recruiting

CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-05Estimated
Enrollment · participants30Estimated
Source updated2026-10-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.